focus -WSS

focus

author：leisure time 2025-09-28 02:00:45 Page View：54

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approves first blood sugar monitor without finger pricks
Next article： What does generative AI mean for health care? We asked experts

leisure time

Clinic falsely told dozens they had Alzheimer's, suits say

ShawnBlazsekwasoneofseveralpatientstoldincorrectlythathehadAlzheimer'sdiseasebyaclinicunderinvestiga